Shanghai Henlius Biotech

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Shanghai Henlius Biotech sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 5 currently recruiting 1 completed upper quartile by trial count

Shanghai Henlius Biotech: 8 sponsored US clinical trials, 5 recruiting.

Shanghai Henlius Biotech sponsors 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 1 completed. 4 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 2 trials.

Upper-quartile sponsor footprint

Shanghai Henlius Biotech sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 1

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

NCT07477587
RECRUITING Phase 1

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

NCT07176650
RECRUITING Phase 1

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

NCT07160335
RECRUITING Phase 2

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06907615
RECRUITING Phase 3

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006
ACTIVE NOT RECRUITING Phase 3

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

NCT05468489
ACTIVE NOT RECRUITING Phase 3

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257
COMPLETED Phase 3

A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

NCT04740671

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 1
Phase 3 4

Therapeutic Areas

Non-Small Cell Lung Cancer 2
Limited Stage Small Cell Lung Cancer 1
Monoclonal Antibody 1
HER2-positive Gastric Cancer 1
Gastroesophageal-junction Cancer 1
Gastric Cancer 1
Extensive-stage Small-cell Lung Cancer 1
Hepatocellular Carcinoma (HCC) 1
Melanoma 1
Renal Cell Carcinoma 1

What is open in the Shanghai Henlius Biotech pipeline

5 recruiting of 8 indexed (63% open); 1 completed (13%).

Phase mix: 4 late (III/IV) vs 4 early (I/II) (balanced across stages).

Top condition: Non-Small Cell Lung Cancer (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Shanghai Henlius Biotech: open-pipeline peers nationwide

Peers matched on 8 registered trials and 63% open enrollment, not the therapeutic-area sidebar.

Shanghai Henlius Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%20%40%60%80% Total trials Recruiting share Shanghai Henlius BiotechAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Canadian Cancer Trials GroupCellSight TechnologiesCook Children's Health Care SystemNurix Therapeutics
Shanghai Henlius Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Shanghai Henlius Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 63% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Shanghai Henlius Biotech page

8 registered trials is a research-attention snapshot, not an endorsement of Shanghai Henlius Biotech or any single study.

  • 5 of Shanghai Henlius Biotech's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Non-Small Cell Lung Cancer is the condition Shanghai Henlius Biotech studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Shanghai Henlius Biotech pipeline card: 8 registered trials from official public datasets.Report a data error.